Analyst Price Targets — PMN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 21, 2026 12:46 pm | — | Roth Capital | $29.00 | $15.15 | TheFly | ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital |
| July 28, 2026 2:10 pm | Keay Nakae | Chardan Capital | $33.00 | $16.07 | TheFly | ProMIS Neurosciences price target raised to $33 from $20 at Chardan |
| July 27, 2026 8:17 am | Keay Nakae | Chardan Capital | $20.00 | $12.20 | TheFly | ProMIS Neurosciences initiated with a Buy at Chardan |
| July 7, 2026 8:09 pm | — | Roth Capital | $19.00 | $13.55 | TheFly | ProMIS Neurosciences initiated with a Buy at Roth Capital |
| December 1, 2025 1:46 pm | — | H.C. Wainwright | $18.00 | $7.21 | TheFly | ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright |
| July 14, 2025 10:13 am | Raghuram Selvaraju | H.C. Wainwright | $100.00 | $30.00 | TheFly | ProMIS Neurosciences initiated with a Buy at H.C. Wainwright |
Latest News for PMN
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.
Promis Neurosciences NASDAQ: PMN reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer's disease.
Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update.
Total Revenue: $3.3 billion in Q2 2026, up 12% year-over-year.CF Revenue: Global CF revenue grew 11% year-over-year in Q2 2026.CASGEVY Revenue: $76 million in Q
Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PMN.
U.S. House Trading
No House trades found for PMN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.